Table 3 Prognostic factors for local control (LC), Locoregional control (LRC) and metastasis-free survival (MFS)
Local relapse | Locoregional relapse | |||
|---|---|---|---|---|
Variable | Subhazard Ratio (SHR, 95% CI) | p-value | Subhazard Ratio (SHR, 95% CI) | p-value |
Gender | ||||
Male (n = 35) | 1 | p = 0.2 | 1 | p = 0.5 |
Female (n = 11) | 0.5 [0.1–1.6] | 0.7 [0.3–1.9] | ||
Histology | ||||
Non squamous (n = 24) | 1 | p = 0.3 | 1 | p = 0.9 |
Squamous (n = 22) | 1.48 [0.6–3.2] | 0.9 [0.5–1.7] | ||
Age | ||||
< 66 years (n = 23) | 1 | p = 0.4 | 1 | p = 0.9 |
≥ 66 years (n = 23) | 1.4 [0.5–3.7] | 0.9 [0.5–2] | ||
Period between irradiations | ||||
> 24 months (n = 20) | 1 | p = 0.8 | 1 | p = 0.1 |
≤ 24 months (n = 25) | 1.1 [0.4–2.9] | 1.8 [0.8–3.9] | ||
Missing value (n = 1) | ||||
> 12 months (n = 36) | 1 | p = 0.8 | 1 | p = 0.5 |
≤ 12 months (n = 9) | 1.09 [0.3–3.6] | 1.3 [0.5–3.5] | ||
Missing value (n = 1) | ||||
Dose of reirradiation | ||||
BED > 130 Gy (n = 28) | 1 | p = 0.9 | 1 | p = 0.09 |
BED ≤130 Gy (n = 18) | 0.9 [0.3–2.5] | 1.8 [0.9–3.9] | ||
BEDmin ≤50 Gy (n = 22) | 1 | p = 0.16 | 1 | p = 0.06 |
BEDmin > 50 Gy (n = 23) | 0.5 [0.2–1.3] | 0.5 [0.2–1.05] | ||
SABR duration | ||||
≥ 6 days (n = 25) | 1 | p = 0.4 | 1 | p = 0.7 |
< 6 days (n = 20) | 1.5 [0.56–4.11] | 0.9 [0.4–1.8] | ||
Chemotherapy after reirradiation | ||||
Yes (n = 10) | 1 | 1 | ||
No (n = 36) | 1.6 [0.4–5.5] | p = 0.4 | 1.6 [0.7–3.9] | p = 0.2 |
Tumor size | ||||
< 33 mm (n = 22) | 1 | 1 | ||
≥ 33 mm (n = 21) | 1.58 [0.6–4.1] | p = 0.3 | 1.6 [0.8–3.5] | p = 0.18 |
Missing value (n = 3) | ||||
GTV Volume | ||||
< 13 mL (n = 22) | 1 | 1 | ||
≥ 13 mL (n = 22) | 1.49 [0.57–3.95] | p = 0.4 | 1.83 [0.87–3.82] | p = 0.10 |
Missing value (n = 2) | ||||
SABR duration | ||||
≥ 6 days (n = 25) | 1 | p = 0.4 | 1 | p = 0.7 |
< 6 days (n = 21) | 1.51 [0.56–4.1] | 0.87 [0.42–1.79] | ||
Number of fractions | ||||
≤ 3 (n = 16) | 1 | p = 0.09 | 1 | p = 0.9 |
> 3 (n = 30) | 2.85 [0.85–9.6] | 0.99 [0.47–2.1] | ||
Dose per fraction | ||||
> 12 (n = 23) | 1 | p = 0.8 | 1 | p = 0.2 |
≤ 12 (n = 22) | 0.93 [0.35–2.44] | 1.54 [0.74–3.21] | ||
Performans Status - ECOGa | ||||
1 (n = 11) | 1 | p = 0.7 | 1 | p = 0.19 |
0 (n = 27) | 0.78 [0.2–2.9] | 1.8 [0.7–4.4] | ||
Missing value (n = 8) | ||||
Location of relapse | ||||
Peripheral (n = 22) Central | 1 | p = 0.03 | 1 | p = 0.9 |
(n = 24) | 3.2 [1.1–9.5] | 0.9 [0.4–2.1] | ||
Primary stage (at first irradiation) | ||||
IIIA (n = 21) | 1 | p = 0.6 | 1 | p = 0.11 |
IIIB (n = 25) | 1.2 [0.5–3.2] | 1.8 [0.9–3.7] | ||
In-field relapse | ||||
No (n = 17) | 1 | p = 0.2 | 1 | p = 0.2 |
Yes (n = 29) | 2 [0.7–5.9] | 1.6 [0.7–3.6] | ||
In-field relapse and central tumors | ||||
No (n = 26) | 1 | p = 0.04 | 1 | p = 0.8 |
Yes (n = 19) | 2.8 [1.1–7.3] | 0.9 [0.4–1.9] | ||
Adjuvant chemotherapy | ||||
No (n = 36) | 1 | p = 0.4 | 1 | p = 0.2 |
Yes (n = 10) | 1.6 [0.5–5.5] | 1.6 [0.7–3.8] | ||
GTV coverage | ||||
< 95% (n = 22) | 1 | p = 0.1 | 1 | p = 0.07 |
≥ 95% (n = 24) | 0.45 [0.17–1.18] | 0.5 [0.2–1.06] | ||
PTV coverage | ||||
< 90% (n = 23) | 1 | p = 0.17 | 1 | p = 0.04 |
≥ 90% (n = 23) | 0.5 [0.19–1.32] | 0.4 [0.2–0.98] | ||